Page 74 - Read Online

Lin et al. Cancer Drug Resist. 2026;9:14 Page 19 of 19

84. Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus
pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 2024;403:632-44. DOI
PubMed
85. Ribas A, Medina T, Kirkwood JM, et al. Overcoming PD-1 blockade resistance with CpG-A Toll-like receptor 9 agonist vidutolimod in
patients with metastatic melanoma. Cancer Discov 2021;11:2998-3007. DOI PubMed PMC
86. Márquez-Rodas I, Dutriaux C, Saiag P, et al. BO-112 plus pembrolizumab for patients with anti-PD-1-resistant advanced melanoma:
phase II clinical trial SPOTLIGHT-203. J Clin Oncol 2025;43:2806-15. DOI PubMed PMC

Disclaimer/Publisher’s Note: All statements, opinions, and data contained in this publication are solely those of the individual author(s) and
contributor(s) and do not necessarily reflect those of OAE and/or the editor(s). OAE and/or the editor(s) disclaim any responsibility for harm to
persons or property resulting from the use of any ideas, methods, instructions, or products mentioned in the content.

© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License
(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and
reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and
the source, provide a link to the Creative Commons license, and indicate if changes were made.

67